Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine-Reference-Cited by-同舟云学术

Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine

Published:2022-09-12 Issue:12 Volume:18 Page:1388-1398
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Kavanagh Madeline E.^ORCID,Horning Benjamin D.^ORCID,Khattri Roli,Roy Nilotpal,Lu Justine P.,Whitby Landon R.,Ye Elva^ORCID,Brannon Jaclyn C.,Parker Albert,Chick Joel M.,Eissler Christie L.,Wong Ashley J.,Rodriguez Joe L.,Rodiles Socorro,Masuda Kim,Teijaro John R.,Simon Gabriel M.,Patricelli Matthew P.^ORCID,Cravatt Benjamin F.^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

https://www.nature.com/articles/s41589-022-01098-0.pdf

Reference50 articles.

1. Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 16, 843–862 (2017).

2. Hammarén, H. M., Virtanen, A. T., Raivola, J. & Silvennoinen, O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine 118, 48–63 (2019).

3. Spinelli, F. R., Meylan, F., O’Shea, J. J. & Gadina, M. JAK inhibitors: ten years after. Eur. J. Immunol. 51, 1615–1627 (2021).